Ultragenyx Pharmaceutical And Its Partner Mereo Biopharma's Phase 3 Orbit And Cosmic Studies For Setrusumab (UX143) In Osteogenesis Imperfecta Did Not Achieve Statistical Significance Against Reduction In Annualized Clinical Fracture Rate Compared To Placebo Or Bisphosphonates, Respectively
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)Both studies achieved the secondary endpoint of improvements in bone
- Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)
- Both studies achieved the secondary endpoint of improvements in bone mineral density with strong statistical significance
- Ultragenyx will implement significant expense reductions